---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-262641"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T21:43:38.756755+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology enters $330M upfront collaboration with Kyowa Kirin for ziftomenib; potential milestones up to $1.491B

## Summary
- Upfront payment of $330M to Kura; near-term milestones up to $420M including launch of monotherapy R/R setting.
- Additional milestones of $513M for hematologic malignancies, plus up to $228M if field expansion option for solid tumors is exercised.
- Kyowa Kirin to lead ex-US development/commercialization; Kura leads US with joint profit/cost sharing on US commercialization.
- Kura retains rights to next-generation menin inhibitors outside oncology field; exclusivity obligations for both parties.
- Tiered double-digit royalties on ex-US sales of ziftomenib on a country-by-country basis.

## SEC filing metadata
- accession: 0001193125-24-262641
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312524262641/0001193125-24-262641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312524262641/d902118d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-262641
- JSON: https://secwatch.observer/filing/0001193125-24-262641.json
- Plain text: https://secwatch.observer/filing/0001193125-24-262641.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.